These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 33116231)

  • 1. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
    Anselmi M; Hub JS
    Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.
    Darian E; Guvench O; Yu B; Qu CK; MacKerell AD
    Proteins; 2011 May; 79(5):1573-88. PubMed ID: 21365683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
    Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
    J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.
    van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH
    Proc Natl Acad Sci U S A; 2024 Jul; 121(30):e2407159121. PubMed ID: 39012820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.
    Martinelli S; Nardozza AP; Delle Vigne S; Sabetta G; Torreri P; Bocchinfuso G; Flex E; Venanzi S; Palleschi A; Gelb BD; Cesareni G; Stella L; Castagnoli L; Tartaglia M
    J Biol Chem; 2012 Aug; 287(32):27066-77. PubMed ID: 22711529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The loops of the N-SH2 binding cleft do not serve as allosteric switch in SHP2 activation.
    Anselmi M; Hub JS
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33888588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-alpha induces tyrosine phosphorylation and recruitment of the Src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex.
    Bode JG; Schweigart J; Kehrmann J; Ehlting C; Schaper F; Heinrich PC; Häussinger D
    J Immunol; 2003 Jul; 171(1):257-66. PubMed ID: 12817006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
    Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
    J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.
    Calligari P; Santucci V; Stella L; Bocchinfuso G
    Comput Struct Biotechnol J; 2021; 19():6125-6139. PubMed ID: 34900129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulations on the free and complexed N-terminal SH2 domain of SHP-2.
    Wieligmann K; Pineda De Castro LF; Zacharias M
    In Silico Biol; 2002; 2(3):305-11. PubMed ID: 12542415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.
    Müller PJ; Rigbolt KT; Paterok D; Piehler J; Vanselow J; Lasonder E; Andersen JS; Schaper F; Sobota RM
    J Proteomics; 2013 Jun; 84():132-47. PubMed ID: 23584145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
    Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
    J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
    Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
    Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation.
    Zhu G; Xie J; Kong W; Xie J; Li Y; Du L; Zheng Q; Sun L; Guan M; Li H; Zhu T; He H; Liu Z; Xia X; Kan C; Tao Y; Shen HC; Li D; Wang S; Yu Y; Yu ZH; Zhang ZY; Liu C; Zhu J
    Cell; 2020 Oct; 183(2):490-502.e18. PubMed ID: 33002410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity.
    Burmeister BT; Wang L; Gold MG; Skidgel RA; O'Bryan JP; Carnegie GK
    J Biol Chem; 2015 May; 290(19):12058-67. PubMed ID: 25802336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.
    Neel BG; Gu H; Pao L
    Trends Biochem Sci; 2003 Jun; 28(6):284-93. PubMed ID: 12826400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SH2 tyrosine phosphatase shp2 is required for mammalian limb development.
    Saxton TM; Ciruna BG; Holmyard D; Kulkarni S; Harpal K; Rossant J; Pawson T
    Nat Genet; 2000 Apr; 24(4):420-3. PubMed ID: 10742110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.